Patent 7195896 was granted and assigned to GenVec on March, 2007 by the United States Patent and Trademark Office.
The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants.